Jianke.com, China's online healthcare platform, yesterday announced during the Jianke Doctor Rebrand & 2018 Jianke Partners' Conference in Shanghai that they will be entering into a strategic partnership with US-based global pharmaceutical leader Pfizer. Both companies will leverage their leadership in their respective fields and successful practices to implement a patient-focused strategy in terms of retail, hospital services and internet healthcare, in addition to co-creating an omni-channel retail system that combines online and offline channels. The online health platform is the first B2C Internet drug company to be approved and be in full compliance with all medical requirements for operation in Guangdong province and received the Qualification Certificate for Medicine Trading Services on the Internet in 2009. Subsequently, jianke.com has formed strategic partnerships with thousands of drug producers across China, each of whom directly supplies product to the online firm. Ren Xiaoxiu, general manager of national retail business at Pfizer China, said, "Pfizer China will leverage jianke.com's internet-based new retail channel to create our own B2C and online-to-offline businesses as well as develop a brand-new marketing channel. In addition, Pfizer China will capitalize on the resource of over 6,000 physicians specialised in issues related to males at Chinese Grade III, Class A hospitals shared by jianke.com to combine mobile healthcare with our own products with the aim of providing more patients with access to high-quality healthcare and raising awareness among men about the importance of maintaining good health." In the medical drug traceability field, jianke.com plans to implement the blockchain + anti-counterfeit label technology, which establishes one QR code for each item with the aim of assigning a unique identity to each drug in the supply chain system. Each member organisation participating in the traceability of drugs sold on the jianke.com platform will take responsibility for the recording of the drug information on the blockchain throughout the process from production and distribution to sale with the goal of ensuring the traceability of information about each drug sold on the platform. At the event, Jianke.com also announced the new brand image for Jianke Doctor to the public. Currently, the Jianke Doctor platform has 100,000 registered doctors who provide more than 300,000 consultations per day. Xie Fangmin, CEO of jianke.com, explained the main features of the rebranding effort, which include: -upgrades in the efficiency and quality level of the online consultation service through the addition of an AI-powered medical assistant; and -improvement in the management of chronic disease patients through a single disease management programme. The trend Healthcare companies/platforms like Jianke.com and Ping An Good Doctor are capitalising on China’s huge mobile and internet-savvy population to bring healthcare services direct to consumers, and often from the convenience of their handheld smartphone devices. Earlier this month, Ping An Good Doctor showcased a tiny unstaffed clinic that employs artificial intelligence at the Wuzhen World Internet Conference. Patients can sit in the three-square meter clinic and chat with a cloud doctor, called AI Doctor, about their symptoms. The unstaffed clinics have already been piloted in the Wuzhen Scenic Area outside of Shanghai and could be located anywhere from pharmacies to schools and shopping malls to highway service stations.
Chinese online healthcare platform Jianke.com has agreed a strategic partnership with US-based pharmaceutical company Pfizer. Through the collaboration, the partners will use their respective experience and leadership in order to develop patient-centric retail, hospital and internet health care services in China.